Francesco Bertolini Selected Research

ARQ531

10/2020

The new small tyrosine kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Francesco Bertolini Research Topics

Disease

67	Neoplasms (Cancer) 11/2022 - 10/2002
30	Breast Neoplasms (Breast Cancer) 01/2021 - 01/2003
12	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 11/2022 - 09/2006
6	Leukemia 10/2020 - 11/2008
5	Lymphoma (Lymphomas) 01/2022 - 01/2003
5	Neoplasm Metastasis (Metastasis) 01/2017 - 09/2004
4	Residual Neoplasm 10/2021 - 07/2012
4	Hematologic Neoplasms (Hematological Malignancy) 10/2020 - 06/2004
4	Multiple Myeloma 01/2012 - 09/2002
4	Non-Hodgkin Lymphoma (Lymphosarcoma) 09/2006 - 06/2002
3	Triple Negative Breast Neoplasms 03/2022 - 11/2019
3	Cardiovascular Diseases (Cardiovascular Disease) 01/2017 - 02/2005
2	Ovarian Epithelial Carcinoma 11/2022 - 01/2021
2	Carcinogenesis 10/2020 - 02/2011
2	COVID-19 10/2020 - 01/2020
2	Disease Progression 01/2019 - 06/2012
2	Obesity 11/2017 - 05/2013
2	Hemangiosarcoma (Angiosarcoma) 01/2016 - 01/2014
2	Neuroblastoma 01/2016 - 01/2014
2	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 10/2015 - 12/2009
2	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 04/2015 - 11/2008
2	Type 2 Diabetes Mellitus (MODY) 03/2015 - 05/2014
2	Hepatocellular Carcinoma (Hepatoma) 01/2014 - 07/2012
2	Glioblastoma (Glioblastoma Multiforme) 01/2014 - 01/2013
2	Prostatic Neoplasms (Prostate Cancer) 01/2014 - 04/2008
2	Inflammation (Inflammations) 05/2013 - 01/2007
2	Carcinoma (Carcinomatosis) 11/2011 - 10/2009
2	Melanoma (Melanoma, Malignant) 02/2011 - 10/2002
2	Colorectal Neoplasms (Colorectal Cancer) 10/2010 - 09/2003
2	Vascular Remodeling 10/2010 - 01/2008
2	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 07/2005 - 10/2004
1	Cytopenia 11/2022
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2022
1	Pathologic Complete Response 01/2021
1	Hematologic Diseases (Blood Diseases) 01/2021

Drug/Important Bio-Agent (IBA)

10	Pharmaceutical PreparationsIBA 11/2022 - 08/2003
10	Biomarkers (Surrogate Marker)IBA 01/2022 - 09/2002
9	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 08/2016 - 01/2003
9	Bevacizumab (Avastin)FDA Link 06/2015 - 09/2003
8	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2021 - 08/2003
7	Monoclonal AntibodiesIBA 01/2022 - 06/2002
7	Biological ProductsIBA 01/2022 - 11/2005
4	Metformin (Glucophage)FDA LinkGeneric 01/2022 - 05/2014
4	Phosphotransferases (Kinase)IBA 10/2020 - 02/2011
4	Proteins (Proteins, Gene)FDA Link 10/2020 - 07/2012
4	RNA (Ribonucleic Acid)IBA 10/2020 - 06/2004
4	Capecitabine (Xeloda)FDA Link 06/2015 - 10/2008
4	Angiogenesis InhibitorsIBA 10/2011 - 09/2003
3	Poly(ADP-ribose) Polymerase InhibitorsIBA 11/2022 - 04/2015
3	Vinorelbine (Navelbine)FDA LinkGeneric 01/2021 - 06/2015
3	AntibodiesIBA 01/2020 - 09/2002
3	Immune Checkpoint InhibitorsIBA 11/2019 - 11/2017
3	Rituximab (Mabthera)FDA Link 01/2018 - 10/2003
3	Fluorouracil (Carac)FDA LinkGeneric 01/2018 - 03/2009
3	Paclitaxel (Taxol)FDA LinkGeneric 11/2011 - 09/2008
3	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 05/2010 - 05/2003
2	AnthracyclinesIBA 01/2022 - 03/2009
2	LigandsIBA 01/2022 - 11/2019
2	denatonium (denatonium benzoate)IBA 01/2021 - 01/2020
2	Tyrosine Kinase InhibitorsIBA 10/2020 - 10/2015
2	Trastuzumab (Herceptin)FDA Link 01/2018 - 05/2003
2	DNA (Deoxyribonucleic Acid)IBA 01/2018 - 04/2015
2	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 09/2017 - 01/2017
2	NVP-BKM120IBA 02/2016 - 12/2015
2	Activin Receptors (Activin Receptor)IBA 01/2016 - 02/2011
2	BiguanidesIBA 03/2015 - 05/2014
2	EndoglinIBA 05/2014 - 12/2004
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 06/2012 - 06/2012
2	Lenalidomide (CC 5013)FDA Link 01/2012 - 10/2011
2	Gemcitabine FDA Link 11/2011 - 09/2008
2	Cell-Free Nucleic AcidsIBA 10/2010 - 06/2004
2	NucleotidesIBA 08/2010 - 01/2007
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 10/2009 - 09/2004
2	Cyclin D1IBA 10/2008 - 12/2005
2	Cyclin D3IBA 10/2004 - 09/2003
1	Neoplasm Antigens (Tumor Antigens)IBA 01/2022
1	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 01/2022
1	Small Cytoplasmic RNAIBA 10/2021
1	Tyrosine (L-Tyrosine)FDA Link 10/2020
1	Agammaglobulinaemia Tyrosine KinaseIBA 10/2020
1	Proteasome Endopeptidase Complex (Proteasome)IBA 10/2020
1	ibrutinibIBA 10/2020
1	ARQ531IBA 10/2020
1	venetoclaxIBA 01/2020
1	130-nm albumin-bound paclitaxelIBA 11/2019
1	AlbuminsIBA 11/2019
1	atezolizumabIBA 11/2019
1	Decitabine FDA Link 01/2019
1	ATP-Binding Cassette Transporters (ABC Transporters)IBA 01/2018
1	Cetuximab (Erbitux)FDA Link 01/2018
1	NAD (NADH)IBA 01/2018
1	Daunorubicin (Cerubidine)FDA LinkGeneric 01/2018

Therapy/Procedure

37	Therapeutics 11/2022 - 01/2003
26	Drug Therapy (Chemotherapy) 03/2022 - 01/2003
4	Mammaplasty (Breast Reconstruction) 07/2015 - 01/2012
3	Transplantation 01/2021 - 09/2004
2	Conservative Treatment 06/2017 - 07/2015
1	Salvage Therapy 11/2022
1	Immunotherapy 03/2022
1	Heterologous Transplantation (Xenotransplantation) 01/2019